Form 4: Nexalin Technology's Chief Medical Officer, David Owens, Buys Additional Shares
SEC Form 4 Filing
David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,000 shares of common stock at $3.10 per share on February 4, 2025.
Summary
- On February 4, 2025, David Owens, the Chief Medical Officer of Nexalin Technology, Inc., acquired 1,000 shares of the company's common stock.
- The purchase price was $3.10 per share.
- Following this transaction, Owens directly owns 155,793 shares of Nexalin Technology.
Sentiment
Score: 6
Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's prospects. However, the purchase is relatively small, so the impact is moderate.
Positives
- The purchase of shares by a company insider like the Chief Medical Officer can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by investors as it can provide insights into a company's performance and future prospects. Purchases are generally viewed more positively than sales.
Stakeholder Impact
- The purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/04/2025 | Date of transaction: David Owens purchased 1,000 shares of common stock. |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Keywords
Nexalin Technology, David Owens, Chief Medical Officer, stock purchase, insider trading, NXL, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.